Mortality in Cushing’s Disease
Abstract
The causes of premature death in untreated Cushing’s syndrome are vascular disease (myocardial infarction/stroke), uncontrolled diabetes mellitus and complications and infections. Long-term mortality outcome studies on pituitary-dependent Cushing’s disease (CD) are limited to six studies in the English language literature. This paper reviews these studies on CD, other causes of Cushing’s syndrome being excluded, because CD represents 80% of patients with the syndrome. The period covered by these studies (1970–1990) is when transsphenoidal surgery was well established as primary treatment for CD. Two studies were exclusively from surgical centres and are likely biased in favour of surgically resectable adenomas, so this needs to be borne in mind when interpreting their results. The criteria for remission of hypercortisolism and persistent disease were variable. The overall number of patients in each report is small, and the number of deaths even smaller by epidemiological standards giving very wide confidence intervals to the standardised mortality ratios (SMR). Moreover, follow-up time was relatively short (median 10–12 years) for a disease diagnosed in the patients’ late 30s. Notwithstanding the above limitations of retrospective studies, and potential for positive bias, the overall SMR of around 1.5 was not significantly different from the relevant normal population for those patients deemed in remission. However, SMR was significantly worse for those patients with persistent disease. Where it was possible to analyse contributing factors to mortality, the presence of hypertension and diabetes mellitus, in addition to persistence of hypercortisolism, was shown to be significant. It remains possible that an overall SMR in ‘cured’ patients would be significant given a larger cohort, followed for longer, and with more deaths. What is clearly required is a multicentre prospective cohort study with >30 years’ follow-up to answer the question definitively and identify the contributing factors in detail in order to achieve optimum long-term outcome.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypercortisolism is associated with 3.5 to 5 times increased mortality risk compared with the general population.
“Hypercortisolism is associated with an increase in cardiovascular events (myocardial infarction), cerebrovascular events (stroke), sepsis, and thromboembolism with 3.5 to 5 times increased mortality risk compared with the general population (7-11).”
From Approach to the Patient: Diagnosis of Cushing Syndrome (2022) · cites this paper as [7]
Cited by
Sorted by citations
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., Martino, M. C. D., Newell-Price, J. D. C., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 694 · see citing works
The Treatment of Cushing's Disease
Pivonello, R., Leo, M. D., Cozzolino, A., & Colao, A. A. L. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 471 · see citing works
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.
Davi, M., Cosaro, E., Piacentini, S., Reimondo, G., Albiger, N., Arnaldi, G., Faggiano, A., Mantovani, G., Fazio, N., Piovesan, A., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0809 · Cited by 89 · see citing works
“It is known that the consequences of hypercortisolism can lead to the death of the patient, sometimes more rapidly than tumor progression (17, 18).”
Approach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91 · see citing works
“5 to 5 times increased mortality risk compared with the general population (7-11).”
BackgroundPersistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry.
Berr, C., Stieg, M., Deutschbein, T., Quinkler, M., Schmidmaier, R., Osswald, A., Reisch, N., Ritzel, K., Dimopoulou, C., Fazel, J., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0689 · Cited by 78 · see citing works
Cortisol and cardiometabolic disease: a target for advancing health equity
Ortiz, R., Kluwe, B., Lazarus, S. A., Teruel, M. N., & Joseph, J. J. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.08.002 · Cited by 73 · see citing works
Pros and cons of screening for occult Cushing syndrome
Tabarin, A., & Perez, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.51 · Cited by 57 · see citing works
Chuang, M., Chuang, T., Koo, M., & Wang, Y. (2017) · BioMed Research International · doi:10.1155/2017/4210217 · Cited by 45 · see citing works
Mortality in Patients with Endogenous Cushing’s Syndrome
Javanmard, P., Duan, D., & Geer, E. B. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.005 · Cited by 47 · see citing works
Pivonello, R., Arnaldi, G., Scaroni, C. M., Giordano, C. S. D. S., Cannavò, S., Iacuaniello, D., Trementino, L., Zilio, M., Guarnotta, V., Albani, A., et al. (2019) · Endocrine · doi:10.1007/s12020-018-1818-7 · Cited by 43 · see citing works
Mel'nichenko, G. A., Dedov, I. I., Belaya, Z. E., Rozhinskaya, L. Y., Vagapova, G. R., Волкова, Н. И., Grigor’ev, A. Y., Grineva, E. N., Marova, E. I., Mkrtumayn, A. M., et al. (2015) · Problems of Endocrinology · doi:10.14341/probl201561255-77 · Cited by 50 · see citing works
Impact of Technique on Cushing Disease Outcome Using Strict Remission Criteria
Alahmadi, H., Cusimano, M., Woo, K. M., Mohammed, A. A., Goguen, J., Smyth, H., Macdonald, R., Muller, P., Horváth, É., & Kovacs, K. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710001427x · Cited by 29 · see citing works
Minnetti, M., Hasenmajer, V., Sbardella, E., Angelini, F., Simeoli, C., Paola, N. D., Cozzolino, A., Pivonello, C., de Alcubierre, D., Chiloiro, S., et al. (2022) · medRxiv · doi:10.1101/2022.05.12.22275009 · Cited by 25
“Overt GC excess, known as Cushing’s Syndrome (CS), has been associated with increased comorbidities, including cardiovascular disorders, diabetes and immune suppression [9-11], while infectious diseases are considered one of the main causes of death in patients with active CS [12-15].”
BackgroundDevelopment of potent selective competitive-antagonists of the melanocortin type 2 receptor
Bouw, E., Huisman, M., Neggers, S. J. C. M. M., Themmen, A. P. N., van der Lely, A. J., & Delhanty, P. J. D. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.003 · Cited by 22 · see citing works
“However, when eucortisolemia is achieved, the observed mortality rate returns to normal over a 10–20 year follow-up period (Clayton, 2010).”
BackgroundDeath in pediatric Cushing syndrome is uncommon but still occurs
Gkourogianni, A., Lodish, M. B., Zilbermint, M. F., Lyssikatos, C., Belyavskaya, E., Keil, M. F., & Stratakis, C. A. (2014) · European Journal of Pediatrics · doi:10.1007/s00431-014-2427-y · Cited by 19 · see citing works
“A number of studies on mortality in CS in adults are available [1, 4, 6, 7, 9, 17, 18, 22, 25, 26, 30, 33, 35].”
BackgroundChandran, D., Ali, N., Jaryal, A., Jyotsna, V., & Deepak, K. (2013) · Neuroendocrinology · doi:10.1159/000345905 · Cited by 21 · see citing works
Cushing Syndrome Associated Myopathy: It Is Time for a Change
Reincke, M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1069 · Cited by 28 · see citing works
“Late diagnosis of CS is associated with high morbidity and mortality [6].”
BackgroundArterial and Venous Thrombosis in Endocrine Diseases
van Zaane, B., Stuijver, D., Squizzato, A., & Gerdes, V. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1343889 · Cited by 20 · see citing works
PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS.
Albani, A., Perez-Rivas, L., Reincke, M., & Theodoropoulou, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0111 · Cited by 18 · see citing works
Hu, Q.-Z., Kunde, J., Hanke, N., & Hartmann, R. (2015) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2015.04.013 · Cited by 14 · see citing works
“[1,2] As for the majority of this syndrome that are caused by pituitary adenomas and termed Cushing’s disease, the 5 years’ survival is only about 50% if without effective treatments.”
BackgroundAhmed, T., Powner, M. B., Qassem, M., & Kyriacou, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-69466-5 · Cited by 11 · see citing works
White blood cell count: a valuable tool for suspecting Cushing’s syndrome
Paja, M., Merlo, I., Rodríguez-Soto, J., Cruz-Iglesias, E., Moure, M., Elias, C., Oleaga, A., & Egaña, N. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01892-6 · Cited by 10 · see citing works
Truong, H., Nellesen, D., Ludlam, W., & Neary, M. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.877470 · Cited by 10 · see citing works
Current views of the screening and diagnostics of endogenous hypercorticism
Белая, Ж. Е., Рожинская, Л. Я., Mel'nichenko, G. A., & Dedov, I. I. (2012) · Problems of Endocrinology · doi:10.14341/probl201258435-41 · Cited by 10 · see citing works
“36 ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИ, 4, 2012 добиться в 80% случаев, и смертность пациентов в ремиссии не отличается от популяционной [16].”
Long-term outcome in patients after treatment for Cushing’s disease in childhood
Pasternak-Pietrzak, K., Moszczyńska, E., Roszkowski, M., Kot, K., Marczak, E., Grajkowska, W., Pronicki, M., & Szalecki, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226033 · Cited by 9 · see citing works
Shen, A., King, J. A. J., Scott, H. S., Colman, P. G., & Yates, C. J. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1689120 · Cited by 10 · see citing works
Sherry, A. D., Khattab, M., Xu, M. C., Kelly, P., Anderson, J. L., Luo, G., Utz, A. L., Chambless, L., Cmelak, A., & Attia, A. (2019) · Pituitary · doi:10.1007/s11102-019-00992-6 · Cited by 9 · see citing works
Pasternak-Pietrzak, K., Moszczyńska, E., Jurkiewicz, E., & Szalecki, M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2019.0040 · Cited by 11 · see citing works
Baba, N., Kameda, H., Nakamura, A., Cho, K. Y., Nomoto, H., Mitsuhashi, T., Miyoshi, H., & Atsumi, T. (2020) · Endocrine journal · doi:10.1507/endocrj.ej20-0185 · Cited by 7
“In addition, hypertension, diabetes mellitus and hypercortisolism significantly con‐ tribute to mortality [3].”
BackgroundDisruption of Rich club Connectivity in Cushing's Disease.
Xu, C.-X., Jiang, H., Zhao, Z.-J., Sun, Y.-H., Chen, X., Sun, B.-M., Sun, Q.-F., & Bian, L.-G. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2020.12.146 · Cited by 5 · see citing works
Behaviour disorder caused by Cushing's syndrome in an older person.
Damanti, S., Abbate, C., Chiodini, I., Cesari, M., Nestola, T., Belloni, G., Mandelli, C., Mari, D., & Lucchi, T. (2018) · Age and Ageing · doi:10.1093/ageing/afy102 · Cited by 4 · see citing works
Pronóstico del paciente tratado de síndrome de Cushing
Aulinas, A., Valassi, E., & Webb, S. M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.008 · Cited by 19 · see citing works
Two cases of pancreatic neuroendocrine tumors with ectopic ACTH syndrome during their disease course
Murakami, M., Hirahata, K., Fujimori, N., Yamamoto, T., Oda, Y., Kozono, S., Ueda, K., Ito, T., Nakamura, M., & Ogawa, Y. (2024) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01908-5 · Cited by 4 · see citing works
“Not only the malignancy of the tumor itself and resistance to treatment but also complications, including impaired immune function due to hypercortisolemia, have been reported as causes of poor prognosis, and appropriate hormone control is important to improve prognosis [1, 9].”
InfluentialBlom, D. J. (2011) · South African Family Practice · doi:10.1080/20786204.2011.10874107
Trummer, C., Pandis, M., Theiler‐Schwetz, V., Schmitt, L., Obermayer-Pietsch, B. M., Gellner, V., Simon, A., & Pilz, S. (2024) · Endocrine · doi:10.1007/s12020-024-03832-1 · Cited by 2 · see citing works
“Overall, CS is associated with an increased mortality, mainly caused by cardiovascular and infectious diseases, that correlates with the duration of disease activity [4, 5].”
BackgroundSpecific focus on the basal dura for improving Cushing’s disease surgery: a cohort study
Baussart, B., Hudelist, B., Villa, C., Hage, M., Jouinot, A., Reina, V., Barat, M., Leclercq, D., Passeri, T., Touraine, P., et al. (2025) · Neurosurgical review · doi:10.1007/s10143-025-03656-1 · Cited by 1 · see citing works
“…to severe clinical and biological manifestations, including altered physical appearance, hypertension, diabetes mellitus, muscle weakness, obesity, neuropsychiatric manifestations, and increased risks of infections and cardio-vascular disease and therefore an increased risk of mortality [6–9].”
Modern principles of the diagnosis and conservative treatment of Cushing disease
Abdali, A., Astafeva, L., Kalinin, P., Trunin, Y., Chernov, I., Сhmutin, G. E., Badshahzar, A., Sherzad, G., & Keith, S. (2020) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2010-08 · Cited by 1 · see citing works
Cushing's syndrome: a problem of excess cortisol
Peate, I., & Holmes, E. (2014) · doi:10.12968/bjha.2014.8.2.80 · Cited by 1
Surgical approaches to Cushing's disease.
Smith, P., & Hanks, J. (2011) · Current problems in surgery · doi:10.1067/j.cpsurg.2011.06.006 · Cited by 1 · see citing works
Suryadevara, C. M., Salcedo-Sifuentes, J., Little, A., Yuen, K. C. J., Mendoza, M. M., Gardner, P. A., Zenonos, G., Silverstein, J., Kim, A., Evans, J. J., et al. (2026) · Neurosurgery · doi:10.1227/neu.0000000000003992
Development and validation of clinical screening systems for Cushing disease in the United States
Salcedo-Sifuentes, J. E., Mehta, S., Suryadevara, C. M., Bergsneider, M., Yuen, K. C. J., Gardner, P. A., Silverstein, J. M., Kim, A. H., Evans, J. J., Barkhoudarian, G., et al. (2025) · Pituitary · doi:10.1007/s11102-025-01583-4
Pereira, A. J. G., Batista, R. L., Cunha-Neto, M. B. C., Cescato, V. Â. S., da Silva, G. O., Fragoso, M. C. B. V., Nishimoto, I. N., Glezer, A., & Machado, M. C. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.10.005
Zaffari, J. P. (2025) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv6n1-004
Kamińska, M., Strzoda, A., Juda, A., Rojek, K., Strzoda, A., Sowiński, W., & Polak, A. (2022) · Journal of Education, Health and Sport · doi:10.12775/jehs.2023.13.01.030
A Stratified Approach for Cushing’s Syndrome Diagnosis
Chávez-Castillo, M., Rojas, J., Aguirre, M., Villalobos, M., Salazar, J. J., Bello, L., Áñez, R., Olivar, L. C., Calvo, M. C. C., Herazo-Beltrán, Y., et al. (2019) · Global Journal of Health Science · doi:10.5539/gjhs.v11n10p55
“…with CS, followed by poorly-controlled diabetes mellitus and complicated opportunistic infections (Clayton, Raskauskiene, Reulen, & Jones, 2011); risk for these comorbidities is especially alarming in patients with CS since they display a doubled risk of all-cause mortality (Clayton, 2010).”
BackgroundCushing's Syndrome From Pituitary Microadenoma and Pulmonary Nodules.
Tating, D., Montevirgen, N. D. S., & Cajucom, L. (2016) · Oncology Nursing Forum · doi:10.1188/16.onf.136-140
“The estimated five-year survival rate with untreated Cushing’s disease involving patients with ACTH-secreting pituitary adenoma is 50%, resulting from vascular disease, stroke, myocardial infarction, uncontrolled diabetes mellitus, and infection (Clayton, 2010).”
Diabetes mellitus type 2: a new indication for hypercortisolism screening?
Волкова, Н. И., Antonenko, M. I., & Ganenko, L. A. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5545 · Cited by 1 · see citing works
[Modern aspects of surgery for cushing's disease].
Abdali, A., Astafeva, L., Trunin, Y., Chernov, I., Sidneva, Y. G., Abdilatipov, A. A., & Kalinin, P. (2021) · Voprosy neirokhirurgii imeni N N Burdenko · doi:10.17116/neiro202185041111
- Authors
- Clayton, R. N.
- Affiliations
- Royal Stoke University Hospital (GB)
- Corresponding author
- Clayton, R.N.
- ORCID
- Clayton, R.N.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 92
- Issue
- Suppl. 1
- Pages
- 71-76
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2028311382
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 2 · 2022: 8 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 1
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- Cushing's disease, pituitary-dependent Cushing's syndrome, mortality, standardized mortality ratio, transsphenoidal surgery, persistent disease, hypertension, diabetes mellitus, vascular disease, long-term outcomes
- MeSH terms
- Adenoma, Humans, Pituitary Neoplasms, Treatment Outcome, Pituitary ACTH Hypersecretion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
